<DOC>
	<DOCNO>NCT02100917</DOCNO>
	<brief_summary>This study randomize Trastuzumab-controlled double-blind parallel-group study .</brief_summary>
	<brief_title>Bioequivalence Study Evaluating Pharmacokinetics DMB-3111 Trastuzumab Healthy Japanese Male Adults</brief_title>
	<detailed_description />
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Healthy Japanese male adult 2 . Body Mass Index ( BMI ) 17.6 26.4 kg/m² time screen BMI = Body Weight ( kg ) / [ Height ( ) ] ² 3 . The individual freely consent participate receive detailed explanation clinical study completely understanding thereof , capacity follow precaution provide write consent . 1 . History hypersensitivity component Trastuzumab diphenhydramine drug 2 . Use ethical drug within 2 week investigational product administration overthecounter drug within 1 week investigational product administration would affect study participation opinion investigator subinvestigators ( except diphenhydramine , use concomitantly present clinical trial drug apply locally systemic action ) 3 . History allergic symptom bronchial asthma urticaria would affect study participation opinion investigator subinvestigators 4 . History cardiac disorder , hypertension , coronary artery disease ( e.g. , myocardial infarction , angina ) , and/or vascular disorder ; ongoing palpitation , shortness breath , and/or tachycardia</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Biosimilarity</keyword>
	<keyword>Similarity</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Phase I</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Healthy Male Volunteers</keyword>
	<keyword>Single-dose</keyword>
	<keyword>HER-2</keyword>
	<keyword>Oncology</keyword>
</DOC>